Abstract: The present invention relates to a process for recognizing the risk of falling ill after an arthropod bite, which is characterized in that after the prick or bite of a host by an arthropod, nucleic acid of the host and nucleic acid of a pathogen passed along or onn by the arthropod are demonstrated to be present in the latter. Furthermore, the invention concerns a kit suited for the purpose of carrying out the process.

Abstract: A whole body stereotaxis apparatus comprising a base plate (2) to accommoe a patient, two side strips (4, 6) which are attached to the base plate (2) at the marginal or side edges thereof and laterally delimit the base plate (2) and to which arches (10, 12) extending over the base plate (2) can be attached, characterized in that a central strip (8) is mounted on the base plate (2) and comprises bores (22) to accommodate accessories.

Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.

Abstract: The invention relates to an antisense oligonucleotide suitable for inhibiting the expression of aromatase, the antisense oligonucleotide being obtainable by the following steps:(a) construction of antisense oligonucleotides along the entire length of coding and regulatory regions of an aromatase DNA and/or transcripts thereof, the antisense oligonucleotides overlapping;(b) incubation of an aromatase-expressing cell with one or more of the antisense oligonucleotides of (a); and(c) detection of the inhibition of the aromatase expression as usual, as well as identification of the antisense oligonucleotide(s) responsible for this. Furthermore, the invention relates to a process for preparing such an antisense oligonucleotides as well as its use.

Abstract: The present invention relates to a bonding reagent, which is characterized in that it comprises a first bonding component specific for the hemagglutinin-neuraminidase molecule of a Newcastle Disease Virus and a second bonding component specific for a costimulatorily acting molecule of an effector cell.Furthermore, this invention concerns a process for the production of the bonding reagent as well as a vaccine containing the bonding reagent and inactivated tumor cells.

Abstract: The present invention relates pharmaceutical compositions comprising a conjugate of an active substance, a linker and a carrier for the treatment and/or diagnosis of inflammatory diseases. The present invention further relates to methods using such pharmaceutical compositions for treating and diagnosing inflammatory diseases including, but not limited to, infectious diseases, autoimmune diseases, skin diseases, and inflammatory neovascularization.

Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.

Abstract: The invention relates to a method for the preparation of glycoconjugates of phosphorus amides with the general formula ##STR1## where the connection of the sugar with the phosphoric acid amide mustard residue, and the ifosfamide mustard residue, respectively, occurs preferably in the 1-position, and where R.sub.1 and R.sub.2 ; which can be the same or different, denote hydrogen, lower C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.6 haloalkyl and where as sugar there can be present mono-, di-, or polysaccharides in all existing isomeric and enantiomeric forms, wherein in a known way protected brominated sugars are conjugated with the respective phosphorus compounds, and freed of the protective residues, and to the use of said compounds as anti-tumour drugs.

Abstract: The present invention relates to a vector expressing a single chain of antibody variable domains coupled to the peptidoglycan associated lipoprotein (PAL) of E. coli. Furthermore, the present invention relates to the use of this vector and to a method for the isolation of cells producing specific antibodies.

Abstract: The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi.The present invention also provides a process for obtaining this vaccine, as well as new monoclonal antibodies and antigens.

Abstract: The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi.The present invention also provides a process for obtaining this vaccine, as well as new monoclonal antibodies and antigens.